SCHEMBL6399116

SCHEMBL6399116

O=P(O)(O)c1cccc(O)c1C(O)CCc1cccc(O)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.42
ERAP2 Q6P179 1/20 0.42
ERAP1 Q9NZ08 1/20 0.42
OPRK1 P41145 5/20 0.41
OPRM1 P35372 4/20 0.41
OPRD1 P41143 4/20 0.41
HTR2B P41595 1/20 0.40
DRD2 P14416 2/20 0.40
DRD1 P21728 2/20 0.40
TAAR1 Q96RJ0 1/20 0.40
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
DRD3 P35462 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
TYR P14679 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396461 0.94 OPRK1 (0.40) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6396010 0.88 ANPEP (0.41) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6399767 0.88 ENPP2 (0.38) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6398059 0.86 ANPEP (0.38) ANPEPERAP2ERAP1HTR2BADRB2
SCHEMBL6396016 0.82 MGLL (0.39) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6397757 0.81 ANPEP (0.40) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6399106 0.81 ANPEP (0.40) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6401616 0.80 ANPEP (0.43) ANPEPERAP2ERAP1OPRK1OPRM1
SCHEMBL6399784 0.80 ACHE (0.42) ANPEPERAP2ERAP1
SCHEMBL6395861 0.80 ANPEP (0.43) ANPEPERAP2ERAP1OPRK1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ANPEP 211/4885ERAP2 261/4885ERAP1 304/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ANPEP 191/4885ERAP2 248/4885ERAP1 272/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ANPEP 211/4885ERAP2 261/4885ERAP1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.